Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression
Abstract Anti-angiogenic therapies for melanoma have not yet been translated into meaningful clinical benefit for patients, due to the development of drug-induced resistance in cancer cells, mainly caused by hypoxia-inducible factor 1α (HIF-1α) overexpression and enhanced oxidative stress mediated b...
Guardado en:
Autores principales: | Valentin-Florian Rauca, Laura Patras, Lavinia Luput, Emilia Licarete, Vlad-Alexandru Toma, Alina Porfire, Augustin Catalin Mot, Elena Rakosy-Tican, Alina Sesarman, Manuela Banciu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/03c6b0e8b4f24848a334855428de8d78 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant.
por: Choon Kit Tang, et al.
Publicado: (2013) -
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Ryszard Smolarczyk, et al.
Publicado: (2018) -
Codelivery of thioridazine and doxorubicin using nanoparticles for effective breast cancer therapy
por: Jin X, et al.
Publicado: (2016) -
Progress in Nanocarriers Codelivery System to Enhance the Anticancer Effect of Photodynamic Therapy
por: Yu-Ling Yang, et al.
Publicado: (2021) -
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment
por: Peng Y, et al.
Publicado: (2018)